Clinical Trials Logo

Low-grade Serous Ovarian Cancer clinical trials

View clinical trials related to Low-grade Serous Ovarian Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03875820 Active, not recruiting - Pancreatic Cancer Clinical Trials

Phase I Trial of Defactinib and VS-6766.

FRAME
Start date: December 12, 2017
Phase: Phase 1
Study type: Interventional

This is a multi-centre, investigator-initiated, dose escalation, Phase I trial of the combination of the FAK inhibitor, Defactinib (VS-6063), and the dual RAF/MEK inhibitor, VS-6766 (RO5126766) in patients with advanced solid tumours. VS-6766 (RO5126766) is the same compound as CH5126766. There are two parts to this study, the dose escalation phase and the dose expansion phase. In the dose escalation phase, cohorts of 3 to 6 patients will be enrolled to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). This will be followed by a dose expansion phase to further characterise the safety and tolerability and to assess the pharmacodynamic activity of the combination.